公开(公告)号：US20120079570A1

公开(公告)日：2012-03-29

申请号：US12891476

申请日：2010-09-27

Applicant: Yan Fu ,  Nadarajah Asokan ,  Ville Aarni

Inventor： Yan Fu ,  Nadarajah Asokan ,  Ville Aarni

IPC: H04L9/32

CPC classification number: H04L9/3213 ,  H04L9/3234 ,  H04L63/0428 ,  H04L63/083 ,  H04L63/102

Abstract: Techniques for accelerated authentication include receiving first data that indicates a first portion of user credentials for a first user but not a second portion. It is verified whether the first portion of user credentials is valid. If the first portion of user credentials is valid, then second data that indicates a valid value for the second portion of user credentials for the first user is sent. Other techniques include receiving first data that indicates a first portion of user credentials for a first user but not a second portion of user credentials for the first user. A first message that indicates the first portion of user credentials is sent to a remote process that initiates authentication of the first user based on the first portion of user credentials before receiving second data that indicates the second portion of user credentials for the first user.

Abstract translation: 用于加速认证的技术包括接收指示第一用户的用户凭证的第一部分而不是第二部分的第一数据。 验证用户凭据的第一部分是否有效。 如果用户凭证的第一部分有效，则发送指示用于第一用户的第二部分用户凭证的有效值的第二数据。 其他技术包括接收指示第一用户的用户凭证的第一部分的第一数据，而不是第一用户的用户凭证的第二部分。 指示用户凭证的第一部分的第一消息被发送到远程进程，该远程进程在接收指示第一用户的用户凭证的第二部分的第二数据之前，基于用户凭证的第一部分来发起对第一用户的认证。

公开(公告)号：US08084021B2

公开(公告)日：2011-12-27

申请号：US12203116

申请日：2008-09-02

Applicant: Zailin Yu ,  Yan Fu

Inventor： Zailin Yu ,  Yan Fu

IPC: C07K14/52 ,  A61K38/20

CPC classification number: A61K38/38 ,  A61K47/643 ,  A61K47/646 ,  C07H21/04 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/5403 ,  C07K14/5431 ,  C07K14/765 ,  C07K14/79 ,  C07K2319/00 ,  Y02A50/463 ,  A61K2300/00

Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。

公开(公告)号：US20110304619A1

公开(公告)日：2011-12-15

申请号：US12849670

申请日：2010-08-03

Applicant: Yan Fu ,  Jin Yang ,  Xiaofeng Zhu ,  Zhenggang Yuan

Inventor： Yan Fu ,  Jin Yang ,  Xiaofeng Zhu ,  Zhenggang Yuan

IPC: G06T17/00

CPC classification number: G06T17/00 ,  G06K9/00201

Abstract: A method, apparatus, system, article of manufacture, and data structure provide the ability to extract a primitive quadric surface from point cloud data. Point cloud data is obtained in 3D space. The point cloud data is segmented to create a disjoined surface and a smooth surface segment based on spatial connectivity and surface smoothness. One or more shapes are extracted from the point cloud data using geometric fitting. The geometric fitting searches for one or more quadric surface parameters of a given type of model that provides a best agreement between selected points from the point cloud data and a resultant model.

Abstract translation: 方法，装置，系统，制品和数据结构提供从点云数据中提取原始二次曲面的能力。 点云数据在3D空间中获得。 点云数据被分割以基于空间连通性和表面平滑度创建分离的表面和平滑的表面段。 使用几何拟合从点云数据中提取一个或多个形状。 几何拟合搜索给定类型的模型的一个或多个二次曲面参数，其提供来自点云数据的所选点与最终模型之间的最佳一致性。

公开(公告)号：US20070253409A1

公开(公告)日：2007-11-01

申请号：US10590375

申请日：2005-03-24

Applicant: Yan Fu ,  Haitao Hu

Inventor： Yan Fu ,  Haitao Hu

IPC: H04L12/28

CPC classification number: H04L12/185 ,  H04L29/12009 ,  H04L29/12783 ,  H04L61/35 ,  H04L63/101 ,  H04L63/104

Abstract: The present invention discloses a method for implementing multicast services, which includes: preset a mapping relation between a multicast user address and a multicast group address; acquire a request packet sent by the multicast user who requests to join in the multicast group; determine whether the multicast group address in request packet is the same as that corresponding to the multicast user in the established mapping relation according to the multicast user address and multicast group address carried in the request packet. If yes, allow the multicast user to join in the multicast group. Otherwise, reject the multicast user from joining in the multicast group. The present invention can open the preset multicast resources to the preset multicast user with speed and pertinence. At the same time, it limits the maximum number of multicast groups that each multicast user is allowed to join in, which can effectively control multicast service bandwidth and further protect the network equipment.

Abstract translation: 本发明公开了一种实现组播业务的方法，包括：预先配置组播用户地址与组播组地址之间的映射关系; 获取请求加入组播组的组播用户发送的请求报文; 根据组播用户地址和请求包中携带的组播组地址，确定请求报文中的组播组地址是否与建立的映射关系中的组播用户对应的组播组地址相同。 如果是，允许组播用户加入组播组。 否则，拒绝组播用户加入组播组。 本发明可以以预定的组播用户的速度和针对性开放预设的组播资源。 同时限制了每个组播用户可以加入的组播组的最大数量，从而有效地控制组播业务带宽，进一步保护网络设备。

公开(公告)号：US07244833B2

公开(公告)日：2007-07-17

申请号：US10609346

申请日：2003-06-26

Applicant: Zailin Yu ,  Yan Fu

Inventor： Zailin Yu ,  Yan Fu

IPC: C12N5/10 ,  C12N15/19 ,  C12N15/62 ,  C12N15/63 ,  C12N15/64

CPC classification number: A61K38/38 ,  A61K47/643 ,  A61K47/646 ,  C07H21/04 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/5403 ,  C07K14/5431 ,  C07K14/765 ,  C07K14/79 ,  C07K2319/00 ,  Y02A50/463 ,  A61K2300/00

Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。

公开(公告)号：US20050048523A1

公开(公告)日：2005-03-03

申请号：US10766102

申请日：2004-01-27

Applicant: Patrick Schnable ,  Feng Liu ,  Yan Fu

Inventor： Patrick Schnable ,  Feng Liu ,  Yan Fu

IPC: C12N1/15 ,  C12N1/21 ,  C12N15/10 ,  C12N15/62 ,  C12Q1/68 ,  C07H21/04

CPC classification number: C12N15/1086 ,  C07K2319/21 ,  C12N15/1065 ,  C12N15/62

Abstract: Compositions and methods for identifying nucleotide fragments that contain an open reading frame are provided. Compositions comprise a nucleotide sequence that encodes, in each of the three possible reading frames, an ATG start codon and a histidine tag, and vectors comprising such a nucleotide sequence. The vectors may be provided with cloning sites for insertion of nucleotide sequences of interest 5′ or 3′ to the 3-frame His-tag DNA sequence. Vectors also are provided with cloning sites for inserting nucleotide sequences of interest 3′ of the ATG start codon and 5′ of the 3-frame His-tag DNA sequence.

Abstract translation: 提供了用于鉴定包含开放阅读框架的核苷酸片段的组合物和方法。 组合物包含在三个可能的阅读框中的每一个中编码ATG起始密码子和组氨酸标签的核苷酸序列，以及包含这种核苷酸序列的载体。 可以向载体提供用于将感兴趣的5'或3'的核苷酸序列插入3框架His标签DNA序列的克隆位点。 载体还提供有用于插入ATG起始密码子的3'和3框His标签DNA序列的5'的感兴趣的核苷酸序列的克隆位点。

公开(公告)号：US5494513A

公开(公告)日：1996-02-27

申请号：US499458

申请日：1995-07-07

Applicant: Yan Fu ,  Jian Ding ,  James J. Beaudoin

Inventor： Yan Fu ,  Jian Ding ,  James J. Beaudoin

IPC: C04B14/04 ,  C04B28/02 ,  C04B28/06

CPC classification number: C04B28/02 ,  C04B14/047 ,  C04B28/065 ,  C04B2111/00784 ,  C04B2111/40

Abstract: Lightweight concrete products, useful for example in blocks, wall panels, floor and roof slabs, in which zeolite is a major component, its content in the cementing material of the products exceeding 50 wt. %. Depending on application, zeolite may be non-treated or calcined at a temperature enabling the surface activation of the zeolite and resulting high surface energy. Zeolite thus treated will work as both pozzolanic material and bubble-generating agent. Strengthening agents are used to improve compressive strength of the products. Also, a binding material, useful for hazardous waste stabilization, comprising zeolite as a major component, is proposed.

Abstract translation: 轻质混凝土制品，例如在块体，墙板，地板和屋顶板中有用，其中沸石是主要成分，其在产品的固井材料中的含量超过50wt。 ％。 根据应用，沸石可以在能够使沸石表面活化并产生高表面能的温度下进行未处理或煅烧。 如此处理的沸石将作为火山灰材料和发泡剂起作用。 加强剂用于提高产品的抗压强度。 此外，提出了一种用于危险废物稳定化的粘合材料，其包含沸石作为主要成分。

公开(公告)号：US20150197733A9

公开(公告)日：2015-07-16

申请号：US14343694

申请日：2012-09-10

Applicant: Yongzhang Luo ,  Peng Liu ,  Xinan Lu ,  Yang Chen ,  Yan Fu ,  Guodong Chang ,  Daifu Zhou

Inventor： Yongzhang Luo ,  Peng Liu ,  Xinan Lu ,  Yang Chen ,  Yan Fu ,  Guodong Chang ,  Daifu Zhou

IPC: C12N9/14 ,  C12Q1/34

CPC classification number: C12N9/14 ,  A61K38/18 ,  A61K47/60 ,  C07K14/475 ,  C12Q1/00

Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.

Abstract translation: 本发明公开了一种新的抗肿瘤药物，其包含内皮抑素的突变体。 突变体包含内皮抑素的ATP结合位点中的突变，并且具有降低的ATP酶活性和增加的抗血管生成活性。

公开(公告)号：US08832141B2

公开(公告)日：2014-09-09

申请号：US12683829

申请日：2010-01-07

Applicant: Yan Fu ,  Xiaoyu Gong ,  Ting Zou

Inventor： Yan Fu ,  Xiaoyu Gong ,  Ting Zou

IPC: G06F17/30 ,  H04L12/911 ,  H04L12/54 ,  H04L12/24 ,  H04L29/06 ,  H04L12/923

CPC classification number: H04L41/0893 ,  H04L47/70 ,  H04L47/745 ,  H04L47/762 ,  H04L47/824 ,  H04L47/828 ,  H04L63/20

Abstract: A method, a device and a system for combination of resource admission control are provided. The system includes the policy determination combination device and multiple bearer and transmission devices. The combination device combines functions and interfaces of two or multiple kinds of arbitrary policy determination devices in systems of different standards, and has multiple interfaces to be connected with the bearer and transmission devices, and selects the corresponding interface working protocol according to the type of bearer and transmission device. Multiple bearer and transmission devices are connected with the policy determination combination device by different interfaces. By setting policy determination combination device, the combination of policy determination devices is realized with a few changes to the current network. When there are multiple types of bearer and transmission devices in a management domain, the number of the policy determination devices can be efficiently reduced, and the cost of setting up the network and maintenance can be reduced. Also, it is propitious to collaborate and combine different standards and to improve speed of industrialization.

Abstract translation: 提供了一种用于组合资源准入控制的方法，装置和系统。 该系统包括策略确定组合设备和多个承载和传输设备。 组合设备将不同标准系统中的两种或多种任意策略确定设备的功能和接口相结合，具有与承载和传输设备连接的多个接口，并根据承载类型选择对应的接口工作协议 和传输设备。 多个承载和传输设备通过不同的接口与策略确定组合设备连接。 通过设置策略确定组合设备，通过对当前网络的几个变化来实现策略确定设备的组合。 当在管理域中存在多种类型的承载和传输设备时，可以有效地减少策略确定设备的数量，并且可以降低建立网络和维护的成本。 此外，有利于合作，结合不同标准，提高工业化进程。

公开(公告)号：US08796285B2

公开(公告)日：2014-08-05

申请号：US13377138

申请日：2010-06-03

Applicant: Hailin Zhang ,  Jinlong Qi ,  Diqun Zhang ,  Kewei Wang ,  Fan Zhang ,  Yan Fu ,  Yi Mi ,  Wen Xu ,  Xiaona Du ,  Yibing Wu ,  Qingzhong Jia ,  Shuangge Yang

Inventor： Hailin Zhang ,  Jinlong Qi ,  Diqun Zhang ,  Kewei Wang ,  Fan Zhang ,  Yan Fu ,  Yi Mi ,  Wen Xu ,  Xiaona Du ,  Yibing Wu ,  Qingzhong Jia ,  Shuangge Yang

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00

CPC classification number: C07D487/04

Abstract: The present invention provides new pyrazol-[1,5-a]-pyrimidone derivates and pharmaceutical compositions comprising said compounds and one or more pharmaceutically acceptable carriers or diluents. The uses of the compounds for the manufacture of potassium channel openers, anti-epilepsy medicaments, anti-anxiety medicaments and analgesic medicaments are also provided in the present invention.

Abstract translation: 本发明提供新的吡唑并[1,5-a] - 嘧啶酮衍生物和包含所述化合物和一种或多种药学上可接受的载体或稀释剂的药物组合物。 本发明还提供了化合物用于制造钾通道开放剂，抗癫痫药物，抗焦虑药物和镇痛药物的用途。